29.08.2024 16:29:10
|
Orgenesis Announces Real-World Data Of ORG-101 CAR-T Therapy For CD19+ Acute Lymphoblastic Leukemia
(RTTNews) - Orgenesis Inc. (ORGS), Thursday announced positive results from a real-world study of CD19 CAR-T therapy, ORG-101, in patients with CD19+ Acute Lymphoblastic Leukemia.
According to the company, ORG-101 uses a third-generation lentiviral vector with a proprietary CAR construct, along with streamlined and decentralized onsite production and analytic testing.
The real-world study revealed that ORG-101 achieved a complete response of 82 percent in adult patients and 93 percent in pediatric patients, with a low incidence of Cytokine Release Syndrome in both groups.
The biotech company plans to initiate its own Phase 1/2 clinical multicenter study at the General University Hospital of Patras in Greece.
Meanwhile, Harley Street Healthcare Group aims to set up a Global Cancer Initiative along with Orgenesis, focusing on democratizing Advance Therapies and supporting further clinical development.
Currently, Orgenesis's stock is trading at $0.70, up 0.77 percent on the Nasdaq.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Orgenesis Inc Registered Shsmehr Nachrichten
Keine Nachrichten verfügbar. |